Protocol Ledger

NCT04310020 · Phase II · ACTIVE NOT RECRUITING

Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients

Interventional Phase II clinical trial protocol NCT04310020 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-01-13 Enrollment: 47 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04310020
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)47 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04310020
Protocol FieldVerified Registry Value
NCT IdentifierNCT04310020
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment47 participants (ESTIMATED)
Registered Start Date2021-01-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI